Method for Treating Pervasive Development Disorders

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

1 . A method for treating an individual having an autistic disorder, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes to promote changes in autistic behavior by ameliorating a symptom of the autistic disorder. 
     
     
         2 . The method of  claim 1 , wherein the symptom comprises an impairment in making eye contact with another individual. 
     
     
         3 . The method of  claim 1 , wherein the symptom comprises a lack of social interaction. 
     
     
         4 . The method of  claim 1 , wherein the symptom comprises a delay in or lack of spoken language. 
     
     
         5 . The method of  claim 1 , wherein the symptom comprises a repetitive pattern of behavior such as arm flapping. 
     
     
         6 . The method of  claim 1 , wherein the symptom comprises hyperactivity. 
     
     
         7 . The method of  claim 1 , wherein the symptom comprises a lack of a formed bowel movement. 
     
     
         8 . The method of  claim 1 , wherein the symptom comprises a lack of toilet training 
     
     
         9 . The method of  claim 1  wherein the administering digestive enzymes comprises administering digestive enzymes comprising approximately 4,000 to approximately 60,000 U.S.P. Units/tablet on a daily basis. 
     
     
         10 . The method of  claim 1 , wherein the digestive enzymes comprise lipase, amylase, protease, cellulose, sucrase, or maltase either singularly or in any combination thereof. 
     
     
         11 . The method of  claim 1 , wherein the administering of digestive enzymes comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the individual. 
     
     
         12 . The method of  claim 11 , wherein the digestive enzymes are administered at least about three times per day. 
     
     
         13 . The method of  claim 1 , wherein the digestive enzymes comprise a pancreatic enzyme. 
     
     
         14 . A method for treating an individual having a disorder using digestive enzymes, the disorder comprising ADD (attention deficit disorder) or ADHD (attention deficit hyperactivity disorder), the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes to ameliorate a symptom of the disorder. 
     
     
         15 . The method of  claim 14 , wherein the symptom comprises hyperactivity. 
     
     
         16 . The method of  claim 14 , wherein the symptom comprises a lack of attention. 
     
     
         17 . The method of  claim 14 , wherein the administering of digestive enzymes comprises administering at least one tablet of digestive enzymes comprising approximately 4,000 to approximately 12,000 U.S.P. Units/tablet on a daily basis. 
     
     
         18 . The method of  claim 14 , wherein the digestive enzymes comprise lipase, amylase, protease, cellulose, sucrase, or maltase either singularly or in any combination thereof. 
     
     
         19 . The method of  claim 14 , wherein the digestive enzymes comprise a pancreatic enzyme. 
     
     
         20 . A method for treating an individual having a disorder comprising Autism, ADD (attention deficit disorder) or ADHD (attention deficit hyperactivity disorder), the method comprising administering digestive enzymes to the individual to promote protein digestion to improve a symptom of the disorder. 
     
     
         21 . A method for treating an autistic disorder in an individual, who suffers from symptoms of autism and digestive symptoms, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes. 
     
     
         22 . The method of  claim 21  wherein the digestive enzymes contain chymotrypsin. 
     
     
         23 . The method of  claim 21  wherein the digestive enzymes contain trypsin. 
     
     
         24 . The method of  claim 21  wherein the digestive enzymes contain amylases. 
     
     
         25 . The method of  claim 21  wherein the digestive enzymes contain lipases. 
     
     
         26 . A method for treating an autistic disorder in an individual who suffers from symptoms of autism and a lack of toilet training, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes. 
     
     
         27 . The method of  claim 26  wherein the digestive enzymes contain chymotrypsin. 
     
     
         28 . The method of  claim 26  wherein the digestive enzymes contain trypsin. 
     
     
         29 . The method of  claim 26  wherein the digestive enzymes contain amylases. 
     
     
         30 . The method of  claim 26  wherein the digestive enzymes contain lipases. 
     
     
         31 . A method for treating an autistic disorder in an individual who suffers from symptoms of autism and a gastrointestinal dysfunction, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes. 
     
     
         32 . The method of  claim 31  wherein the digestive enzymes contain chymotrypsin. 
     
     
         33 . The method of  claim 31  wherein the digestive enzymes contain trypsin. 
     
     
         34 . The method of  claim 31  wherein the digestive enzymes contain amylases. 
     
     
         35 . The method of  claim 31  wherein the digestive enzymes contain lipases. 
     
     
         36 . A method for determining if an individual exhibiting a symptom of a pervasive developmental disorder (PDD) has improved after the administration of a dose of secretin or digestive enzymes, the method comprising making a quantitative, post-administration measurement of a PDD symptom in the individual, and comparing the post-administration measurement of the PDD symptom to a pre-administration measurement of the PDD symptom, wherein a decrease in one or more symptoms of PDD indicates that the individual has improved. 
     
     
         37 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures social behavior. 
     
     
         38 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures imitation. 
     
     
         39 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures body use. 
     
     
         40 . The method of  claim 36  wherein the quantitative, post-administration measurement measures object use. 
     
     
         41 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures adaptation to change. 
     
     
         42 . The method of  claim 36  wherein the quantitative, post-administration measurement measures visual response. 
     
     
         43 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures listening response. 
     
     
         44 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures taste, smell, touch response and use. 
     
     
         45 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures fear. 
     
     
         46 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures verbal communication. 
     
     
         47 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures non-verbal communication. 
     
     
         48 . The method of  claim 36 , wherein the quantitative, post-administration measurement measures activity level. 
     
     
         49 . The method of  claim 36 , wherein the measure is a quantitative measure of general impression. 
     
     
         50 . The method of  claim 36 , wherein the quantitative, post-administration measurement re is a Childhood Autism Rating Scale measurement.